Levodopa Initiation in Phase 3 Trials of Tavapadon, a Selective D1/D5 Agonist for Early Parkinson’s Disease
Objective: To evaluate motor improvements in adults with early Parkinson’s disease (PD) who initiated levodopa (LD) during phase 3 trials of tavapadon. Background: Tavapadon, an…Genetic Variation in KCNJ6 Gene Increases Risk of Impulse Disorders in Parkinson’s Disease: A Two-Cohort Study
Objective: To investigate the association between polymorphisms related to reward and punishment processing, and the development of impulse control disorders (ICDs) and compulsive behaviors (CBs)…MDS-UPDRS Part III Cannot Be Reliably Reduced for Prognostic Modeling in Early Parkinson’s Disease
Objective: To determine whether subsets of MDS-UPDRS Part III items have equal or better prognostic value than the full scale for initiation of dopaminergic therapy…Clinical Approach to Impulse Control–Related Behavioural Disorders in Parkinson’s Disease: A Scoping Review
Objective: We aimed to summarize the definitions, underlying neurobiological mechanisms, validated assessment tools (for both screening and rating), management strategies, and future directions for each…Exploratory Efficacy Analysis of Tavapadon Versus MAO-B Inhibitors in People With Early Parkinson’s Disease
Objective: To evaluate the effect of tavapadon vs monoamine oxidase B inhibitors (MAO-BIs) on motor function in people with early Parkinson’s disease (PD). Background: In…Comparative Effectiveness of Tavapadon Versus Real-world Oral Standard of Care Treatments in Parkinson’s Disease With Motor Fluctuations: an Indirect Comparison Analysis
Objective: To compare clinical-trial tavapadon with real-world oral standard of care (SoC) in patients with Parkinson’s disease (PD) experiencing motor fluctuations. Background: In the phase…Sublingual Apomorphine Tolerability in Clinical Practice: 18-months Post launch experience in Europe
Objective: Describe the post-marketing safety profile of Sublingual apomorphine (SL-APO) in Europe during the first 18 months after launch. Background: SL-APO is an on-demand therapy…Dopamine Agonist-Associated Dropped Head Syndrome in Parkinson’s Disease: A Case Series
Objective: We present a series of three patients with Parkinson’s disease who developed dropped head syndrome (DHS) associated with dopamine agonist therapy, highlighting a potentially…Case of Head Drop as an Adverse Drug Reaction to Dopamine Agonists and Regulatory Evaluation
Objective: RLS can be treated with NEDA, generally in lower dosing than PD. We review a case of HD possibly caused by the DA treatment…Treatment Patterns in Parkinson’s Disease in Kyrgyzstan: Evidence from a Kyrgyz PD Cohort
Objective: To characterize treatment patterns and access to antiparkinsonian medications among patients with Parkinson’s disease (PD) in Kyrgyzstan. Background: Access to treatment for PD remains…
- 1
- 2
- 3
- …
- 16
- Next Page »